Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LyRICX
2023-509287-26-00Phase 2Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of irinotecan, carboplatin, oxaliplatin, fluorouracil, capecitabine and 1 more in gastroesophageal junction adenocarcinoma, gastric adenocarcinoma and esophageal adenocarcinoma (EAC) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Progression-free survival 1 and Neurotoxicity. Planned start Oct 2024; status: authorised.
02
Drugs
irinotecancarboplatinoxaliplatinfluorouracilcapecitabine
03
Conditions
gastroesophageal junction adenocarcinomagastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2023-509287-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509287-26-00.